• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无标准可调节心血管风险因素的 ST 段抬高型心肌梗死(STEMI)患者——他们有多常见,其结局如何?

ST-Segment-Elevation Myocardial Infarction (STEMI) Patients Without Standard Modifiable Cardiovascular Risk Factors-How Common Are They, and What Are Their Outcomes?

机构信息

Cardiothoracic and Vascular Health Kolling Institute and Department of Cardiology Royal North Shore Hospital Northern Sydney Local Health District St Leonards Australia.

Charles Perkins Centre University of Sydney Australia.

出版信息

J Am Heart Assoc. 2019 Nov 5;8(21):e013296. doi: 10.1161/JAHA.119.013296. Epub 2019 Nov 1.

DOI:10.1161/JAHA.119.013296
PMID:31672080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6898813/
Abstract

Background Programs targeting the standard modifiable cardiovascular risk factors (SMuRFs: hypertension, diabetes mellitus, hypercholesterolemia, smoking) are critical to tackling coronary heart disease at a community level. However, myocardial infarction in SMuRF-less individuals is not uncommon. This study uses 2 sequential large, multicenter registries to examine the proportion and outcomes of SMuRF-less ST-segment-elevation myocardial infarction (STEMI) patients. Methods and Results We identified 3081 STEMI patients without a prior history of cardiovascular disease in the Australian GRACE (Global Registry of Acute Coronary Events) and CONCORDANCE (Cooperative National Registry of Acute Coronary Syndrome Care) registries, encompassing 42 hospitals, between 1999 and 2017. We examined the proportion that were SMuRF-less as well as outcomes. The primary outcome was in-hospital mortality, and the secondary outcome was major adverse cardiovascular events (death, myocardial infarction, or heart failure, during the index admission). Multivariate regression models were used to identify predictors of major adverse cardiovascular events. Of STEMI patients without a prior history of cardiovascular disease 19% also had no history of SMuRFs. This proportion increased from 14% to 23% during the study period (=0.0067). SMuRF-less individuals had a higher in-hospital mortality rate than individuals with 1 or more SMuRFs. There were no clinically significant differences in major adverse cardiovascular events at 6 months between the 2 groups. Conclusions A substantial and increasing proportion of STEMI presentations occur independently of SMuRFs. Discovery of new markers and mechanisms of disease beyond standard risk factors may facilitate novel preventative strategies. Studies to assess longer-term outcomes of SMuRF-less STEMI patients are warranted.

摘要

背景 针对标准可调节心血管风险因素(SMuRFs:高血压、糖尿病、高胆固醇血症、吸烟)的计划对于在社区层面解决冠心病至关重要。然而,SMuRF 缺乏的个体发生心肌梗死并不罕见。本研究使用 2 个连续的大型多中心登记处,检查 SMuRF 缺乏的 ST 段抬高型心肌梗死(STEMI)患者的比例和结局。

方法和结果 我们在澳大利亚 GRACE(全球急性冠状动脉事件登记处)和 CONCORDANCE(急性冠状动脉综合征协同国家登记处)登记处中确定了 3081 例无心血管疾病既往史的 STEMI 患者,该登记处包括 1999 年至 2017 年间的 42 家医院。我们检查了 SMuRF 缺乏的比例以及结局。主要结局是院内死亡率,次要结局是主要不良心血管事件(索引入院期间死亡、心肌梗死或心力衰竭)。使用多变量回归模型确定主要不良心血管事件的预测因素。在无心血管疾病既往史的 STEMI 患者中,有 19%也没有 SMuRFs 既往史。在此期间,这一比例从 14%增加到 23%(=0.0067)。与有 1 种或多种 SMuRFs 的个体相比,SMuRF 缺乏的个体院内死亡率更高。两组在 6 个月时主要不良心血管事件无临床显著差异。

结论 大量且不断增加的 STEMI 发作独立于 SMuRFs 发生。除标准危险因素外,发现新的疾病标志物和机制可能有助于制定新的预防策略。需要评估 SMuRF 缺乏的 STEMI 患者的长期结局的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5688/6898813/fb7e185d14a1/JAH3-8-e013296-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5688/6898813/f7b4b65f3fb1/JAH3-8-e013296-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5688/6898813/fb7e185d14a1/JAH3-8-e013296-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5688/6898813/f7b4b65f3fb1/JAH3-8-e013296-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5688/6898813/fb7e185d14a1/JAH3-8-e013296-g002.jpg

相似文献

1
ST-Segment-Elevation Myocardial Infarction (STEMI) Patients Without Standard Modifiable Cardiovascular Risk Factors-How Common Are They, and What Are Their Outcomes?无标准可调节心血管风险因素的 ST 段抬高型心肌梗死(STEMI)患者——他们有多常见,其结局如何?
J Am Heart Assoc. 2019 Nov 5;8(21):e013296. doi: 10.1161/JAHA.119.013296. Epub 2019 Nov 1.
2
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.非标准可调节风险因素的 STEMI 患者的死亡率:SWEDEHEART 注册研究数据的性别细分分析。
Lancet. 2021 Mar 20;397(10279):1085-1094. doi: 10.1016/S0140-6736(21)00272-5. Epub 2021 Mar 9.
3
Outcomes of ST Segment Elevation Myocardial Infarction without Standard Modifiable Cardiovascular Risk Factors - Newer Insights from a Prospective Registry in India.无标准可调节心血管危险因素的 ST 段抬高型心肌梗死的结局-来自印度前瞻性登记研究的新见解。
Glob Heart. 2023 Mar 16;18(1):13. doi: 10.5334/gh.1189. eCollection 2023.
4
Mortality and Cardiovascular Outcomes in Patients Presenting With Non-ST Elevation Myocardial Infarction Despite No Standard Modifiable Risk Factors: Results From the SWEDEHEART Registry.尽管没有标准可改变的风险因素,但出现非 ST 段抬高型心肌梗死的患者的死亡率和心血管结局:来自 SWEDEHEART 登记处的结果。
J Am Heart Assoc. 2022 Aug 2;11(15):e024818. doi: 10.1161/JAHA.121.024818. Epub 2022 Jul 25.
5
Characteristics and Outcomes of Young Patients With ST-Elevation Myocardial Infarction Without Standard Modifiable Risk Factors.无标准可调节危险因素的年轻 ST 段抬高型心肌梗死患者的特征和结局。
Am J Cardiol. 2023 Sep 1;202:81-89. doi: 10.1016/j.amjcard.2023.06.045. Epub 2023 Jul 7.
6
Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors.越来越多的 ST 段抬高型心肌梗死患者的冠状动脉粥样硬化程度不能用标准的可改变的危险因素来很好地解释。
Eur J Prev Cardiol. 2017 Nov;24(17):1824-1830. doi: 10.1177/2047487317720287. Epub 2017 Jul 13.
7
Infarct severity and outcomes in ST-elevation myocardial infarction patients without standard modifiable risk factors - A multicenter cardiac magnetic resonance study.无标准可调节风险因素的 ST 段抬高型心肌梗死患者的梗死严重程度和结局 - 一项多中心心脏磁共振研究。
Eur J Intern Med. 2024 Jan;119:78-83. doi: 10.1016/j.ejim.2023.08.013. Epub 2023 Aug 25.
8
Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry.首次出现 ST 段抬高心肌梗死患者的标准可修正风险因素数量与死亡率:来自中国急性心肌梗死注册登记研究的观察。
BMC Med. 2022 Jul 6;20(1):217. doi: 10.1186/s12916-022-02418-w.
9
Mortality of patients presented with acute ST-segment elevation myocardial infarction according to the status of standard modifiable cardiovascular risk factors.根据标准可改变心血管危险因素的状况,急性 ST 段抬高型心肌梗死患者的死亡率。
Am J Med Sci. 2024 May;367(5):328-336. doi: 10.1016/j.amjms.2024.01.025. Epub 2024 Feb 5.
10
Standard modifiable cardiovascular risk factors in patients with acute coronary syndrome: A report from multicenter percutaneous coronary intervention registry.急性冠状动脉综合征患者的标准可调节心血管危险因素:多中心经皮冠状动脉介入治疗注册研究报告。
J Cardiol. 2023 Jun;81(6):571-576. doi: 10.1016/j.jjcc.2023.01.009. Epub 2023 Feb 8.

引用本文的文献

1
Added prognostic value of fat attenuation index and CT-derived fractional flow reserve over plaque burden in suspected CAD patients without standard modifiable risk factors.在无标准可改变危险因素的疑似冠心病患者中,脂肪衰减指数和CT衍生的血流储备分数相对于斑块负荷的额外预后价值。
Afr Health Sci. 2024 Sep;24(3):444-452. doi: 10.4314/ahs.v24i3.49.
2
Strategies for assessing and preventing cardiovascular disease risk in inflammatory bowel disease patients: A meta-analysis and meta-regression and bibliometric review.评估和预防炎症性肠病患者心血管疾病风险的策略:一项荟萃分析、元回归分析和文献计量学综述
PLoS One. 2025 Jul 28;20(7):e0327734. doi: 10.1371/journal.pone.0327734. eCollection 2025.
3

本文引用的文献

1
Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention.对 480,000 名成年人的冠心病的基因组风险预测:对一级预防的影响。
J Am Coll Cardiol. 2018 Oct 16;72(16):1883-1893. doi: 10.1016/j.jacc.2018.07.079.
2
Utilizing state-of-the-art "omics" technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease.利用最先进的“组学”技术和生物信息学来识别冠状动脉疾病的新生物学机制和生物标志物。
Microcirculation. 2019 Feb;26(2):e12488. doi: 10.1111/micc.12488. Epub 2018 Jul 23.
3
Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors.
Poor Mental Health Status as a Risk Factor and Prognosticator in SMuRF-Less Acute Myocardial Infarction.
心理健康状况不佳作为无SMuRF的急性心肌梗死的危险因素和预后指标
J Clin Med. 2025 Apr 11;14(8):2645. doi: 10.3390/jcm14082645.
4
In-Hospital Outcomes in Patients With Acute Myocardial Infarction and No Standard Modifiable Cardiovascular Risk Factors Across Varying Body Mass Index: Findings From the CCC-ACS Project.不同体重指数下无标准可改变心血管危险因素的急性心肌梗死患者的院内结局:CCC-ACS项目的研究结果
J Am Heart Assoc. 2025 Apr;14(7):e037651. doi: 10.1161/JAHA.124.037651. Epub 2025 Mar 26.
5
Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort.心血管疾病预防中的精准医学:美国队列中多血统多基因风险评分的临床验证
Nutrients. 2025 Mar 6;17(5):926. doi: 10.3390/nu17050926.
6
Efficacy of sacubitril/valsartan on improving clinical symptoms in patients with acute myocardial infarction complicated with heart failure: a retrospective study.沙库巴曲缬沙坦对改善急性心肌梗死合并心力衰竭患者临床症状的疗效:一项回顾性研究
PeerJ. 2025 Feb 11;13:e18873. doi: 10.7717/peerj.18873. eCollection 2025.
7
Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Less) Study.中东动脉粥样硬化性心血管疾病患者缺乏标准可改变风险因素。约旦缺乏标准可改变风险因素(SMuRF-Less)研究。
Vasc Health Risk Manag. 2025 Feb 5;21:39-50. doi: 10.2147/VHRM.S499355. eCollection 2025.
8
Plasma proteomics improves prediction of coronary plaque progression.血浆蛋白质组学可改善对冠状动脉斑块进展的预测。
Eur Heart J Cardiovasc Imaging. 2025 Mar 3;26(3):489-499. doi: 10.1093/ehjci/jeae313.
9
Health status outcomes after acute myocardial infarction in patients without standard modifiable risk factors.无标准可改变危险因素的患者急性心肌梗死后的健康状况结局
Am Heart J. 2025 Mar;281:123-132. doi: 10.1016/j.ahj.2024.11.018. Epub 2024 Dec 3.
10
Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors.伴有和不伴有标准可改变风险因素的急性冠状动脉综合征患者生存情况的性别差异。
Clin Res Cardiol. 2025 Jun;114(6):681-689. doi: 10.1007/s00392-024-02563-7. Epub 2024 Nov 12.
正常 LDL 胆固醇水平与无风险因素的亚临床动脉粥样硬化有关。
J Am Coll Cardiol. 2017 Dec 19;70(24):2979-2991. doi: 10.1016/j.jacc.2017.10.024.
4
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry.年轻人心肌梗死后的心血管风险和他汀类药物适用性:Partners YOUNG-MI 注册研究。
J Am Coll Cardiol. 2018 Jan 23;71(3):292-302. doi: 10.1016/j.jacc.2017.11.007. Epub 2017 Nov 12.
5
Socioeconomic Equity in the Receipt of In-Hospital Care and Outcomes in Australian Acute Coronary Syndrome Patients: The CONCORDANCE Registry.澳大利亚急性冠状动脉综合征患者住院治疗及预后的社会经济公平性:CONCORDANCE注册研究
Heart Lung Circ. 2018 Dec;27(12):1398-1405. doi: 10.1016/j.hlc.2017.08.019. Epub 2017 Sep 20.
6
Fine particulate matter and cardiovascular disease: Comparison of assessment methods for long-term exposure.细颗粒物与心血管疾病:长期暴露评估方法的比较
Environ Res. 2017 Nov;159:16-23. doi: 10.1016/j.envres.2017.07.041. Epub 2017 Jul 29.
7
Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors.越来越多的 ST 段抬高型心肌梗死患者的冠状动脉粥样硬化程度不能用标准的可改变的危险因素来很好地解释。
Eur J Prev Cardiol. 2017 Nov;24(17):1824-1830. doi: 10.1177/2047487317720287. Epub 2017 Jul 13.
8
Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.1990年至2015年全球、区域和国家10种心血管疾病病因负担
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052. Epub 2017 May 17.
9
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.1980 - 2015年全球、区域和国家249种死因的预期寿命、全死因死亡率和死因别死亡率:全球疾病负担研究2015的系统分析
Lancet. 2016 Oct 8;388(10053):1459-1544. doi: 10.1016/S0140-6736(16)31012-1.
10
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲临床实践心血管疾病预防指南:欧洲心脏病学会和其他学会关于临床实践心血管疾病预防的第六联合工作组(由10个学会的代表和特邀专家组成)由欧洲心血管预防与康复协会(EACPR)特别贡献制定。
Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.